Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

Key Points

• Compass Pathways expects to complete its FDA submission for COMP360 in the fourth quarter and is targeting a commercial launch for treatment-resistant depression in the first half of 2027, pending approval and regulatory rescheduling of psilocybin.
• COMP360 could be administered only two to four times annually, with an anticipated six-hour monitoring period and a potential annual cost broadly comparable to SPRAVATO’s $50,000–$65,000 range.
• The company is preparing treatment sites, reimbursement programs and a commercial team for a gradual rollout, while advancing a late-stage PTSD trial and exploring additional opportunities including alcohol-use disorder.

Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027.

Speaking at Deutsche Bank’s Healthcare Summit, Chief Financial Officer Teri Loxam said the company has completed two Phase III trials in treatment-resistant depression, or TRD, that were “highly statistically significant.” The company is also conducting a late-stage trial of COMP360 in post-traumatic stress disorder, which it views as a potential follow-on indication.

The company is using a rolling submission and review process with the FDA and received a Priority Review Voucher in April. Chief Commercial Officer Lori Englebert said the voucher increases the frequency of interactions with the FDA and provides for a target review time of one to two months after the NDA is completed. However, she said there remains uncertainty over whether the agency will also take up to 60 days for its acceptance period.

Following a potential FDA approval, COMP360 would require rescheduling by the Drug Enforcement Administration because psilocybin is currently a Schedule I substance. Englebert said the DEA is required by statute to reschedule a product with an approved medical use within 90 days, although a February executive order could potentially accelerate that process for psychedelic therapies. She said Compass has also been working to prepare states to complete their own rescheduling processes within 30 days of DEA action.

Potential Label and REMS Framework

Chief Patient Officer Dr. Steve Levine said Compass expects a broad label for the treatment of TRD. Based on the company’s Phase III studies, he said a potential label could describe treatment initiation as two doses administered no sooner than three weeks apart, followed by further dosing at clinician discretion or as clinically indicated.

Levine said patients could receive COMP360 two to four times annually, with some patients potentially needing fewer doses and others requiring additional treatment. He contrasted this with Johnson & Johnson’s SPRAVATO, which he said is generally administered 25 to 50 times per year for TRD patients.

Compass expects a Risk Evaluation and Mitigation Strategy, or REMS, comparable to the program used for SPRAVATO. Levine said the anticipated key distinction would be the monitoring period: Compass expects six hours of monitoring for COMP360, compared with two hours for SPRAVATO.

Commercial Preparation and Reimbursement

Englebert said approximately 8,000 sites are currently certified to administer SPRAVATO, with the number growing by roughly 500 sites per quarter. She said Compass has begun making contingent offers to potential sales-force hires and expects its commercial team to cover both treatment sites and referring physicians.

Levine said the company has worked with care providers through strategic collaborations and has deployed a medical science liaison team to engage with sites. He said the facilities administering SPRAVATO were built as platforms for multiple interventional psychiatric treatment options rather than as single-product clinics.

On reimbursement, Levine said Compass applied several years ago for CPT codes specific to in-office administration of psychedelic treatments. Those Category III codes have been approved and are active, according to the company, and could progress to Category I after approval of new products. Compass also intends to seek a J-code after approval to support a buy-and-bill model.

Englebert said Compass has been in discussions with payers since the release of 26-week data from its COMP005 study. She characterized payer feedback as “overwhelmingly positive,” citing the limited number of approved TRD therapies, COMP360’s reported rapid onset among responders and the potential for less-frequent dosing.

Market Positioning and Launch Expectations

The company said it expects to price COMP360 on a per-dose basis, while targeting an annualized cost in the approximate range of SPRAVATO’s stated annual cost of $50,000 to $65,000. Englebert said Compass expects average annual dosing to be around three administrations, within a projected range of two to four doses.

Compass does not plan to target existing SPRAVATO patients, although executives acknowledged that some patients may seek to switch because of the treatment burden associated with frequent visits. Englebert said the company sees a broader untreated market, noting that SPRAVATO is treating about 100,000 patients out of an estimated 4 million TRD patients.

Management expects the launch to begin gradually as sites gain clinical experience with COMP360 and reimbursement processes are established. Englebert said the company is aiming to remove operational barriers through field reimbursement support, site training and patient education, describing the intended approach as “go slow to go fast.”

PTSD and Additional Pipeline Opportunities

In PTSD, Levine said Compass is conducting a Phase IIb/III trial designed as a potential single registrational study, subject to FDA review. He cited an earlier open-label Phase II study involving 22 participants that was principally designed to assess safety and feasibility. The study also generated an efficacy signal on the CAPS-5 measure, with more than 80% of participants responding, he said.

Levine said Compass’s PTSD studies do not include psychotherapy as part of the treatment protocol. Loxam said the company believes the PTSD opportunity could leverage the same treatment-center infrastructure being developed for TRD.

Management also said it sees potential future opportunities in substance-use disorders, particularly alcohol-use disorder, as well as other neuropsychiatric conditions. Loxam said Compass has a library of more than 1,000 compounds, many with preclinical data, and is evaluating business-development opportunities as it builds its commercial and late-stage development capabilities.

About Compass Pathways (NASDAQ:CMPS)

Compass Pathways plc NASDAQ: CMPS is a biotechnology company developing novel treatments for mental health conditions. The company's primary focus is psilocybin therapy, which combines a proprietary investigational formulation with psychological support delivered by trained therapists.

Its lead candidate, COMP360, is a synthetic crystalline formulation of psilocybin being studied primarily for treatment-resistant depression. Compass Pathways has conducted mid- and late-stage clinical trials evaluating COMP360 and has also investigated its potential use in other difficult-to-treat psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.